Health claims database study of cyclosporine ophthalmic emulsion treatment patterns in dry eye patients

Therapeutics and Clinical Risk Management

Volumn 9, Issue 1, 2013, Pages 409-415

  Stonecipher, Karl G ^a   Chia, Jenny ^b   Onyenwenyi, Ahunna ^b   Villanueva, Linda ^b   Hollander, David A ^b  

^a TLC Laser Eye Centers   (United States)

^b ALLERGAN INC   (United States)

Author keywords

Corticosteroids; Cyclosporine; Dry eye syndromes; Inflammation; Medication adherence

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN A; TETRACYCLINE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DATA BASE; DRY EYE; EMULSION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTPATIENT CARE; PRESCRIPTION; TREATMENT DURATION; TRUVEN HEALTH MARKETSCAN RESEARCH DATABASE; VERY ELDERLY; YOUNG ADULT;

EID: 84889790362     PISSN: 11766336     EISSN: 1178203X     Source Type: Journal    
DOI: 10.2147/TCRM.S49754     Document Type: Article

References (17)

1. [No authors listed]. The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf. 2007;5(2): 75-92.
2. Lemp MA. Report of the National Eye Institute/Industry workshop on Clinical Trials in Dry Eyes. CLAO J. 1995;21(4):221-232.
3. Schaumberg DA, Sullivan DA, Buring JE, Dana MR. Prevalence of dry eye syndrome among US women. Am J Ophthalmol. 2003;136(2): 318-326.
4. Schaumberg DA, Dana R, Buring JE, Sullivan DA. Prevalence of dry eye disease among US men: estimates from the Physicians' Health Studies. Arch Ophthalmol. 2009;127(6):763-768.
5. [No authors listed]. The epidemiology of dry eye disease: report of the Epidemiology Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf. 2007;5(2):93-107.
6. Miljanovic B, Dana R, Sullivan DA, Schaumberg DA. Impact of dry eye syndrome on vision-related quality of life. Am J Ophthalmol. 2007;143(3):409-415.
7. Behrens A, Doyle JJ, Stern L, etal; the Dysfunctional Tear Syndrome Study Group. Dysfunctional tear syndrome: a Delphi approach to treatment recommendations. Cornea. 2006;25(8):900-907.
8. Lemp MA. Epidemiology and classification of dry eye. Adv Exp Med Biol. 1998;438:791-803.
9. Rao SN. Topical cyclosporine 0.05% for the prevention of dry eye disease progression. J Ocul Pharmacol Ther. 2010;26(2):157-164.
10. Gayton JL. Etiology, prevalence, and treatment of dry eye disease. Clin Ophthalmol. 2009;3:405-412.
11. Rajpal RK, Digby D, D'Aversa G, Mah F, Hollander DA, Conway T. Intraocular pressure elevations with loteprednol etabonate: a retrospective chart review. J Ocul Pharmacol Ther. 2011;27(3):305-308.
12. [No authors listed]. Management and therapy of dry eye disease: report of the Management and Therapy Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf. 2007;5(2):163-178.
13. Sall K, Stevenson OD, Mundorf TK, Reis BL. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group. Ophthalmology. 2000;107(4):631-639.
14. Rao SN. Reversibility of dry eye deceleration after topical cyclosporine 0.05% withdrawal. J Ocul Pharmacol Ther. 2011;27(6):603-609.
15. Mah F, Milner M, Yiu S, Donnenfeld E, Conway TM, Hollander DA. PERSIST: Physician's Evaluation of Restasis® Satisfaction in Second Trial of topical cyclosporine ophthalmic emulsion 0.05% for dry eye: a retrospective review. Clin Ophthalmol. 2012;6:1971-1986.
16. Byun YJ, Kim TI, Kwon SM, etal. Efficacy of combined 0.05% cyclosporine and 1% methylprednisolone treatment for chronic dry eye. Cornea. 2012;31(5):509-513.
17. American Academy of Ophthalmology Cornea/External Disease Panel. Preferred Practice Pattern® Guidelines. Dry Eye Syndrome-Limited Revision. San Francisco, CA: American Academy of Ophthalmology; 2011. Available from: http://one.aao.org/CE/PracticeGuidelines/PPP_Content.aspx?cid=127dbdce-4 271-471a-b6d9-464b9d15b748. Accessed September 14, 2013.